PT-141 (Bremelanotide): The Peptide for Hormonal and Sexual Health

PT-141 peptide sexual health is no longer a fringe conversation. Bremelanotide — sold as Vyleesi — became the first non-hormonal, FDA-approved treatment for female sexual desire disorder in 2019. It works on the brain, not the body. It targets melanocortin receptors in the hypothalamus to activate dopamine-linked desire pathways. And it has Phase 3 randomised controlled trial data in over 1,200 women to back it.

This article covers exactly what PT-141 is, how it works, what the clinical evidence says, who it is appropriate for, and where its limits are — particularly for women whose low libido is rooted in hormonal disruption from PMOS, perimenopause, or menopause.

What Is PT-141, and Why Does It Matter for Women's Sexual Health?

PT-141 is a synthetic melanocortin peptide derived from alpha-melanocyte stimulating hormone (α-MSH). Its FDA-approved name is bremelanotide. Its brand name is Vyleesi.

It matters because women have been underserved by sexual health medicine for decades. The treatments available before 2019 were either hormonal — testosterone, oestrogen — or approved exclusively for men. When low desire did not respond to hormone optimisation, clinicians had few evidence-based tools. PT-141 changed that by introducing a different entry point: the central nervous system.

This is not a peptide for blood flow. It does not work the way sildenafil or tadalafil does. It works where female desire actually begins — in the brain.

How PT-141 Works: The Melanocortin Mechanism

PT-141 acts directly on melanocortin receptors — specifically MC3R and MC4R — located in the hypothalamus and other brain regions that govern sexual motivation and arousal.

When these receptors are activated, a neurochemical cascade follows:

1. Dopaminergic pathways activate. Dopamine is the primary neurotransmitter for reward, motivation, and anticipatory desire.
2. Sexual motivation increases. This is distinct from peripheral arousal. PT-141 generates what researchers describe as enhanced "wanting" — the psychological drive toward intimacy.
3. Desire precedes arousal. For many women, particularly those with Hypoactive Sexual Desire Disorder (HSDD), the sequence breaks down before arousal begins. PT-141 restores the initiating signal.

Crucially, this mechanism does not alter oestrogen, progesterone, or testosterone. It works regardless of hormonal status. A woman whose labs are optimised but whose desire remains flat can still respond — because the problem was never only in the hormones.

For a broader view of how brain-targeted peptides are reshaping women's care, see Meto's guide to 8 Peptides Being Studied for Women's Hormonal and Metabolic Health in 2026.

PT-141 Peptide Sexual Health and Hormonal Health: The Connection You Should Understand

Low libido rarely exists in isolation for women. It sits inside a cluster of hormonal changes — and that context matters for understanding when and why PT-141 is appropriate.

PMOS and Sexual Dysfunction

Women with Polycystic Metabolic-Ovarian Syndrome (PMOS) frequently experience sexual dysfunction driven by multiple vectors: androgen disruption, insulin resistance, body image distress, and altered dopamine signalling. Standard PMOS management — GLP-1 therapy, hormonal regulation — addresses the metabolic and ovarian components, but does not specifically restore central desire pathways. PT-141 targets that gap directly.

Perimenopause and the Desire Cliff

Perimenopause is one of the most common settings for sudden-onset HSDD. Declining oestrogen alters dopamine receptor sensitivity. Progesterone fluctuation disrupts mood and motivation. Testosterone — which drives desire in women as in men — begins a gradual decline from the mid-thirties that accelerates through this transition.

The result: a woman whose libido was previously normal finds it gone. Hormone replacement helps many. For those it does not fully restore, PT-141 addresses the neurological component that hormones do not reach. Meto's perimenopause programme is the right clinical home for this kind of layered evaluation.

Menopause and Post-Menopausal Desire

The FDA approval of PT-141 covers premenopausal women specifically — that is the licensed indication. Off-label use in post-menopausal women is practiced by some clinicians, but the evidence base is thinner. Women managing menopause should discuss this distinction explicitly with their provider. What works in a premenopausal hormonal profile may require adjustment in a post-menopausal one.

What the Clinical Evidence for PT-141 Sexual Health Actually Shows

The RECONNECT trials are the foundational evidence base for bremelanotide. Two identical Phase 3, randomised, double-blind, placebo-controlled, multicentre clinical trials enrolled a combined 1,267 premenopausal women with HSDD. Bremelanotide 1.75 mg was administered subcutaneously on an as-needed basis.

Primary findings from Kingsberg et al., Obstetrics & Gynecology, 2019:

• Statistically significant improvement in sexual desire scores vs placebo (integrated studies: P < 0.001)
• Statistically significant reduction in distress related to low sexual desire (integrated studies: P < 0.001)
• Approximately 0.5-point improvement in satisfying sexual events per month vs placebo
• Results were consistent across both study arms

Long-term safety data (52-week open-label extension of RECONNECT):

• No new safety signals emerged over 52 weeks
• Sustained improvement in desire and distress scores was maintained
• Safety profile remained consistent with the core phase

Earlier Phase 2 dose-finding work — Clayton et al., Women's Health (London), 2016 — established the dose-response relationship and confirmed tolerability across dose ranges in premenopausal women before Phase 3 was designed.

What the evidence does not show:

The improvement in satisfying sexual events is modest in absolute terms — roughly half an additional event per month. PT-141 is not a guaranteed reversal of HSDD. It is a statistically significant and clinically meaningful improvement for a population that had no non-hormonal, FDA-approved options. That is a meaningful advance. It is not a universal solution.

PT-141 vs. Other Sexual Health Treatments for Women

Understanding where bremelanotide sits relative to other interventions matters before a clinical conversation about it.

The critical differentiator for PT-141: it is the only approved option that targets the brain's desire circuitry without daily dosing. It is used on-demand, which suits women who want a situational rather than continuous intervention.

Meto's progesterone and testosterone pages provide background on the hormonal tools that may complement or precede a PT-141 conversation.

Who Is PT-141 For? Candidacy, Screening, and Contraindications

PT-141 is appropriate for a specific clinical profile. It is not for every woman with low libido.

Appropriate Candidates

• Premenopausal women with diagnosed HSDD — defined as persistent, distressing low sexual desire not explained by medication, medical illness, or relationship factors
• Women who have had low desire assessed and have ruled out treatable hormonal contributors (low testosterone, thyroid dysfunction, elevated prolactin)
• Women whose libido has not fully responded to hormonal optimisation
• Women seeking as-needed rather than daily pharmacological support

Diagnostic Prerequisites

Before prescribing PT-141, a thorough evaluation should include:

1. Sexual function screening — using the Female Sexual Function Index (FSFI) or Female Sexual Distress Scale (FSDS)
2. Hormone panel — total and free testosterone, oestradiol, SHBG, LH, FSH, TSH, prolactin
3. Metabolic baseline — fasting insulin, glucose, HbA1c (relevant if PMOS is in the differential)
4. Cardiovascular assessment — blood pressure measurement and cardiovascular history, given bremelanotide's transient BP effect

Meto's PMOS & Hormonal Health Panel is a strong starting point for the hormonal component of this workup.

Contraindications

• Established cardiovascular disease or uncontrolled hypertension
• Concurrent use of nitrates or nitric oxide donors (risk of hypotension)
• Pregnancy or active attempt to conceive
• High cardiovascular risk where transient blood pressure elevation is unacceptable

How PT-141 Is Used: Dosing, Administration, and Onset

PT-141 is straightforward in practice once candidacy is established.

Standard protocol:

1. Dose: 1.75 mg subcutaneous injection (approved dose); some clinicians initiate at 1 mg to assess tolerability before advancing
2. Timing: Inject 45 minutes before anticipated sexual activity
3. Site: Abdomen or thigh — abdominal injection may reduce peak plasma concentration slightly, which can reduce nausea intensity
4. Frequency: No more than 8 doses per month; not more than once in 24 hours
5. Onset: Effects typically begin within 30–45 minutes
6. Duration: Effects can last 6–12 hours

Nausea mitigation strategies used in practice:

• Eat a low-fat meal approximately 1 hour before injection
• Consider prophylactic ondansetron (Zofran) 4 mg 30 minutes before, if nausea was problematic on prior doses
• Starting at 1 mg for the first dose to establish individual tolerance

PT-141 is available by prescription only as Vyleesi (the brand-name autoinjector). Compounded versions exist, but the regulatory picture around compounded peptides is evolving — read Meto's breakdown of what the FDA's compounded peptides crackdown means for access before engaging with any non-branded source.

Side Effects and Safety: What the Trials Confirm

The RECONNECT trials provide the clearest safety picture. Adverse events were reported in 76.6% of the bremelanotide arm vs 58.2% placebo — the difference driven almost entirely by expected pharmacological effects.

Most common adverse events (bremelanotide arm, RECONNECT):

• Nausea: 40.0% (vs 1.3% placebo) — the primary tolerability concern; typically peaks at 30–60 minutes post-injection and resolves within 3 hours
• Flushing: Reported in a meaningful minority; usually mild and transient
• Headache: Consistent with vasodilatory mechanism
• Injection site reactions: Local redness or bruising; common to all SC peptides

Cardiovascular considerations:

Blood pressure changes are transient and well-characterised. Small, consistent BP increases peak within approximately 4 hours post-dose and return to baseline by 8–10 hours. In healthy, non-hypertensive women, this is clinically acceptable. In women with cardiovascular disease or hypertension, it is not — hence the contraindication.

Transient skin hyperpigmentation was observed in some subjects in earlier nasal spray studies. The subcutaneous formulation carries a lower frequency of this effect, but patients with darker skin tones should be counselled on the possibility.

For a full review of peptide therapy side effect management, see Meto's Peptide Therapy Side Effects FAQ.

PT-141 Peptide Sexual Health and the Regulatory Picture: Why FDA Approval Matters

PT-141's FDA approval in June 2019 is not a technical footnote. It is clinically significant for several reasons.

• It makes bremelanotide the second-ever drug approved for female sexual desire disorder, and the first with a non-hormonal mechanism
• It is the only FDA-approved melanocortin receptor agonist for female sexual dysfunction
• The approval required two independent Phase 3 trials — a higher evidence bar than most research-phase peptides currently circulating in wellness markets
• Pharmaceutical-grade Vyleesi is manufactured under cGMP standards, with verified purity and dosing consistency

The difference between a pharmaceutical-grade, approved product and a compounded or research-grade PT-141 is not trivial. Meto's research peptides vs pharmaceutical grade guide explains why that distinction can affect both efficacy and safety.

Is PT-141 Right for You? What Meto Clinicians Evaluate

PT-141 is rarely the first conversation in a sexual health evaluation. It is the right conversation when hormonal optimisation, relationship context, and psychological factors have been properly considered — and desire remains absent or persistently low.

Meto clinicians approach this evaluation systematically:

• Hormonal baseline first. If testosterone is low, oestradiol is dysregulated, or thyroid function is off, those are the first levers. Correcting them may resolve the desire deficit entirely.
• PMOS and metabolic status. Insulin resistance, androgen excess, and the downstream mood and energy effects of PMOS create conditions where libido suffers as a symptom, not a primary condition. GLP-1 therapy and PMOS-focused hormonal care addresses the root.
• Perimenopause trajectory. Women in early hormonal decline often need a multimodal approach — HRT plus a targeted desire-pathway intervention. PT-141 can play a role in that stack.
• Psychological and relational context. No pharmacological intervention replaces therapy for relationship conflict, trauma, or chronic stress. PT-141 works on the neurological driver of desire; it does not resolve the psychosocial ones.

When the clinical picture supports it, PT-141 is a legitimate, evidence-backed tool — not a shortcut.

The Bottom Line

PT-141 is the only FDA-approved, non-hormonal peptide therapy for female sexual desire disorder. Its mechanism — central melanocortin receptor activation driving dopaminergic desire pathways — is distinct from everything that came before it. The RECONNECT Phase 3 evidence is real, peer-reviewed, and consistent.

It is not appropriate for every woman with low libido. It is most meaningful for those who have already evaluated the hormonal drivers, have addressed what can be addressed, and still experience persistent, distressing absence of desire.

The right place to start is a thorough clinical evaluation — not a prescription for PT-141 in isolation. Hormonal status, metabolic health, and sexual function data together create a picture that guides the most effective, personalised approach.

Discuss Your Sexual and Hormonal Health With a Meto Clinician

Meto specialises in the intersection of hormonal and metabolic health — including conditions like PMOS, perimenopause, and menopause that frequently drive sexual dysfunction. Our clinicians can evaluate your full hormonal and metabolic profile, review whether PT-141 or other sexual health interventions are appropriate for your biology, and build a personalised plan grounded in your actual data.

Most visits are covered by insurance, with an average patient copay of $0–$50.

Start Your Assessment →

Frequently Asked Questions

Is PT-141 the same as Viagra for women?

No. Viagra (sildenafil) targets genital blood flow via PDE5 inhibition — a peripheral, vascular mechanism. PT-141 targets melanocortin receptors in the brain to activate desire at its neurological source. The conditions they address are fundamentally different: sildenafil treats arousal mechanics; PT-141 treats the desire that precedes arousal. Most women with low libido do not have a blood flow problem.

Can PT-141 work if my hormones are already balanced?

Yes — and this is one of its key clinical advantages. PT-141 operates through dopaminergic and melanocortinergic pathways independent of oestrogen, progesterone, or testosterone. Women whose hormones have been optimised through HRT or other therapy but who still experience low desire may respond, because their deficit was always neurological rather than hormonal. That said, hormonal evaluation should still precede any PT-141 prescription to rule out treatable causes.

How quickly does PT-141 work and how long does the effect last?

Onset is typically 30–45 minutes after subcutaneous injection. Most women who respond notice heightened desire and arousal within that window. Effects can last 6–12 hours. This on-demand profile distinguishes PT-141 from flibanserin (Addyi), which requires daily dosing and several weeks before any effect.

Is PT-141 safe to use with hormonal therapies like HRT or progesterone?

There is no pharmacokinetic interaction documented between bremelanotide and standard HRT (oestrogen, progesterone). Clinically, many women use them together — bremelanotide as an as-needed desire intervention, HRT for systemic hormonal support. However, every combination should be reviewed by a prescribing clinician based on your full medication and health profile. Concurrent nitrate use is an absolute contraindication.

Why is PT-141 only FDA-approved for premenopausal women?

The RECONNECT trials were specifically designed and powered for premenopausal women with acquired, generalised HSDD. That is the licensed population. Post-menopausal women were not included as primary trial subjects. Off-label use in post-menopausal women occurs in clinical practice, but lacks the same depth of controlled evidence. Clinicians managing post-menopausal sexual dysfunction need to weigh the transient cardiovascular effects against the hormonal context of that life stage.

What happens if PT-141 causes nausea?

Nausea was the most common adverse event in the RECONNECT trials — reported in 40% of the bremelanotide group, peaking 30–60 minutes after injection and resolving within 3 hours in most cases. Mitigation strategies include eating a light, low-fat meal before injection, using abdominal rather than thigh injection sites, starting at 1 mg rather than 1.75 mg for the first dose, and discussing prophylactic antiemetics (such as ondansetron) with your prescribing clinician.

This article is for informational and educational purposes only. It does not constitute medical advice, a diagnosis, or a treatment recommendation. Always consult a qualified clinician before considering any peptide therapy or sexual health intervention. Last reviewed: May 2026.